Holen Sie sich die Stockscreener-App
4.65
1.06%
-0.05
Handel nachbörslich:
4.84
0.19
+4.09%
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics, Inc. (CVKD) stock price, news, quote and history - Yahoo Finance UK
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics Announces Warrant Inducement Agreement and Issuance of New Warrants – Form 8-K Filing - Minichart
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement - TipRanks
Cadrenal Therapeutics Raises $2.5 Million via Warrant Exercise, Issues New $4.50 Warrants - TradingView
Warrant exercise gives Cadrenal (NASDAQ: CVKD) $2.5M cash - Stock Titan
Cadrenal Therapeutics (NASDAQ: CVKD) amends warrants; registers 590,001 shares - Stock Titan
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy By Investing.com - Investing.com South Africa
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk - TipRanks
Cadrenal Therapeutics Reports Positive Phase 2 HIT Results and FDA Progress for CAD-1005, Announces Q4 2025 Financials - Minichart
Cadrenal Therapeutics Advances CAD-1005 for HIT Treatment: Clinical Progress, Market Opportunity, and Regulatory Insights - Minichart
Cadrenal Therapeutics 2025 10-K: Net loss $13.24M, EPS $(6.64) - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) pivots to CAD-1005 and expands clotting disorder pipeline - Stock Titan
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy - Investing.com
Cadrenal Therapeutics (NASDAQ: CVKD) widens 2025 loss, advances CAD-1005 toward Phase 3 - Stock Titan
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - marketscreener.com
Drug for rare heparin reaction cut clot events by 25%; FDA maps Phase 3 - Stock Titan
Dividend Watch: Is Cadrenal Therapeutics Inc a strong growth stockFed Meeting & Free Community Supported Trade Ideas - baoquankhu1.vn
Cadrenal Therapeutics, Inc. (CVKD) Eps Diluted (TTM) - Zacks Investment Research
CVKD Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily
Fed Meeting: What is Cadrenal Therapeutics Incs valuation compared to sectorGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Buy Signal: Will Cadrenal Therapeutics Inc outperform its industry peersPortfolio Performance Summary & AI Forecasted Stock Moves - baoquankhu1.vn
OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Trading Action: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum - Defense World
CVKD SEC FilingsCadrenal Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Cadrenal Therapeutics, Inc. (CVKD) stock: surges on breakthrough 12-LOX diabetes research - parameter.io
Cadrenal Therapeutics Inc. (CVKD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Trading the Move, Not the Narrative: (CVKD) Edition - Stock Traders Daily
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes - Sahm
CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data - tradingview.com
CVKD: CAD-1005 advances to phase III for HIT, targeting a major unmet need with strong regulatory support - TradingView
Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease - TipRanks
Cadrenal Therapeutics (CVKD) spotlights CAD-1005 12-LOX data in obesity, diabetes and HIT - Stock Titan
Trend Recap: What is Cadrenal Therapeutics Incs valuation compared to sector2026 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Cadrenal Therapeutics Inc expected to post a loss of $1.16 a shareEarnings Preview - TradingView
CVKD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday - Defense World
CVKDCadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - ADVFN Ltd
Cadrenal schedules FDA meeting for HIT drug CAD-1005 - Investing.com India
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewswire
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - Defense World
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial - Investing.com India
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events - Yahoo Finance
Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial By Investing.com - Investing.com Canada
Cadrenal Therapeutics stock surges on Phase 2 trial results - Investing.com South Africa
Cadrenal Therapeutics' recent acquisition makes progress toward phase 3 trial - The Business Journals
Cadrenal Therapeutics stock surges on Phase 2 trial results By Investing.com - Investing.com Nigeria
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):